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P ulmonary hypertension (PH) is characterized by the elevation of pulmonary artery pressure 
(PAP) and pulmonary vascular resistance (PVR) 
caused by pulmonary artery stenosis,  pulmonary 
artery occlusion and/or an increase in pulmonary ﬂow.  
It is sometimes associated with right-sided heart fail-
ure and with high mortality.  The prognosis of patients 
has recently been improved by the development of 
PH-speciﬁc drugs ［1-3］.
　 Atrial septal defect (ASD) is the most frequent 
diseases in adult congenital heart diseases.  Some 
patients with ASD develop PH because of an extraor-
dinary increase in pulmonary ﬂow and/or development 
of pathological changes in pulmonary vascular beds.  In 
general,  the greater pulmonary ﬂow is,  the lower is 
PVR.  In such patients,  PAP decreases with closure 
of the ASD.  On the other hand,  closure of the ASD 
does not necessarily decrease PAP and improve clini-
cal symptoms in patients with high PVR.  At present,  
patients with PH and ASD who have high PVR are 
initially treated with PH-speciﬁc drugs ［4,5］.  After 
PVR has been substantially decreased by PH-speciﬁc 
drugs,  surgical or transcatheter closure of the ASD 
can be performed.  This is called the “Treat and 
Repair” strategy.  According to the guidelines of the 
European Society of cardiology,  closure of the ASD 
is allowed when PVR is less than 5 wood units ［6］.  
When PVR is more than 5 wood units,  PH-speciﬁc 
drugs are used at ﬁrst.
　 There are some problems concerning the “Treat 
and Repair” strategy.  The appropriate cut-oﬀ value of 
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A treatment strategy for patients with pulmonary hypertension (PH) and atrial septal defect (ASD) 
remains unclear.  This study was designed to evaluate the eﬀects of initial repair of ASD followed by 
treatment with PH-speciﬁc drugs in patients with PH and ASD.  Eligible patients receive transcatheter 
ASD closure followed by treatment with bosentan and sildenaﬁl.  Right heart catheterization is per-
formed at baseline and at 12,  24 and 48 weeks.  The primary endpoint is change in pulmonary artery 
pressure and pulmonary vascular resistance from baseline to follow-up.  This study should provide 
valuable information to establish a therapeutic strategy for PH and ASD.
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PVR for performing closure of the ASD remains 
unclear.  PH-speciﬁc drugs often augment pulmonary 
ﬂow because of an increase in ASD shunt ﬂow due to 
a decrease in PVR,  and PAP does not necessarily 
decrease.  An increase in pulmonary ﬂow could 
increase shear stress of the pulmonary vasculature and 
might further damage the pulmonary vasculatures.  We 
hypothesized that ASD closure followed by adminis-
tration of PH-speciﬁc drugs (“Repair and Treat” strat-
egy) would be eﬀective for improving PH because of 
no extraordinary increase in shunt ﬂow in patients 
with PH and ASD.  Thus,  this study was designed to 
evaluate the feasibility of the “Repair & Treat” strat-
egy in patients with PH and ASD.
Endpoints
　 The primary endpoint is change in PAP and PVR 
from baseline to follow-up (12 weeks,  24 weeks and 48 
weeks).  The secondary endpoints are change in brain 
natriuretic peptide,  tricuspid annual plane systolic 
excursion (TAPSE),  right ventricular fractional area 
changes (RVFAC),  tricuspid lateral annular systolic 
velocity waves (RVSʼ) and inferior vena cava diameter 
determined by echocardiography and cardiothoracic 
ratio determined by chest radiography.  We will exam-
ine the safety of ASD closure by assessing the 
patientʼs symptoms,  hemodynamics by the right heart 
catheterization and urine volume.
Eligible Criteria
　 The study population consists of patients with PH 
and ASD.  In patients with ASD,  we check for the 
presence or absence of PH before closure of the ASD.  
We perform chest radiography,  electrocardiography,  
blood examination,  echocardiography and cardiac cath-
eterization.  ASD is deﬁned as a secundum atrial sep-
tal detect by transthoracic and transesophageal echo-
cardiography.  PH is deﬁned as mean PA pressure
25 mmHg and PA wedge pressure 15 mmHg by right 
heart catheterization.  We also evaluate symptoms,  
use of drugs,  blood pressure,  heart rate,  body 
weight,  World Health Organization-functional class 
and 6-minute walk distance.  These examinations are 
performed within one month after obtaining informed 
consent.  Patients who satisfy all of the inclusion cri-
teria are enrolled after diagnosis of PH associated 
with ASD (Table 1).  Patients who meet any of the 
exclusion criteria are excluded from the study (Table 
2).  According to the criteria,  eligible patients will 
give written informed consent.  
Treatment
　 A ﬂow chart of the study is shown in Fig.  1.  
Eligible patients will be undergo transcatheter closure 
of the ASD under general anesthesia in the catheter 
room.  After awaking from general anesthesia,  the 
patient will be moved to the cardiac care unit.  With 
monitoring hemodynamics by right heart catheteriza-
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Table 2　 Exclusion criteria
 1. Patients with PH of other causes (collagen diseases,  lung 
diseases,  pulmonary embolism and heart failure with left ven-
tricular dysfunction)
 2. Patients with other congenital heart diseases.
 3. Patients treated with PAH-speciﬁc drugs.
 4. Patients with Eisenmenger syndrome.
 5. Patients with bleeding or risk of bleeding.
 6. Patients with atrial ﬁbrillation.
 7. Patients with pregnancy or suspected pregnancy or patients 
with breast-feeding.
 8. Patients with moderate renal dysfunction (serum creatinine
1.5 mg/dl).
 9. Patients with moderate liver dysfunction (serum AST or ALT
2-fold of standard value).
10. Patients with hypotension (systolic blood pressure＜90 mmHg)
11. Patients with low cardiac output (cardiac index＜2.2 l/min/m2)
12. Patients with left ventricular dysfunction (left ventricular ejec-
tion fraction＜50%).
13. Any allergy to bosentan and sildenaﬁl.
14. Patients recognized as inappropriate by attending physician.
PH, pulmonary hypertension; PAH, pulmonary arterial hypertension;  
AST, aspartate aminotransferase; ALT, alanine aminotransferase.
Table 1　 Inclusion criteria
 1. Patents diagnosed with ASD 
 2. Patients with mean PAP 25 mmHg and PVR 5 wood units 
and 10 wood units by right heart catheterization within one 
month.
 3. Patients with reduction of PVR after administration of 100% 
oxygen by right heart catheterization within one month after 
giving informed consent.
 4. Patients with defect size of ASD 38 mm.
 5. Patients aged 20-75 years at the time of giving consent.
 6. Patients who agree to be enrolled in the study with signed writ-
ten informed consent.
ASD, atrial septal defect; PAP, pulmonary artery pressure; PVR, 
pulmonary vascular resistance.
tion,  the patient will be administered bosentan 
(62.5 mg)(day 0).  On day 1,  the dose of bosentan will 
be increased to 125 mg/day (twice daily) and the right 
heart catheter will be removed.  On day 3,  a blood 
examination will be performed to check for the pres-
ence or absence of side eﬀects to the liver and kidney.  
If there is no sign of side eﬀects,  sildenaﬁl will be 
added (60 mg/day).  On day 7,  we will perform chest 
radiography,  blood examination,  electrocardiography,  
6-minute walk distance test and echocardiography.  If 
there is no sign of side eﬀects,  the patient will be 
discharged from the hospital.  On day 28,  we will 
again perform chest radiography,  blood examination,  
electrocardiography,  6-minute walk distance test and 
echocardiography.  If there is no sign of side eﬀects,  
titration of bosentan will be initiated to a dose of 
250 mg/day.  We will perform chest radiography,  
blood examination,  electrocardiography,  6-minute 
walk distance test,  echocardiography and right heart 
catheterization at 12,  24 and 48 weeks.
Methods
　 PAP,  right atrium pressure and pulmonary artery 
wedge pressure will be measured by right heart cath-
eterization.  Cardiac output is measured by Fick and 
thermodilution methods.  PVR is calculated by mean 
PAP-PA wedge pressure/cardiac output.  This exam-
ination will be also performed after the inhalation of 
100  oxygen for 10 min.  TAPSE,  RVFAC,  RVSʼ 
and diameter of the inferior vena cava will be mea-
sured by echocardiography.
Study Design
　 This study is a prospective,  interventional,  
non-randomized,  single-center study.  The study was 
started in September 2015 at the Okayama University 
Hospital and will continue until December 2019.  The 
intervention follow-up period is 12 months.  This study 
is approved by the Ethics Committee at Okayama 
University Graduate School of Medicine,  Dentistry 
and Pharmaceutical Sciences (1509-006).  This study 
has been registered at UMIN-CTR (UMIN: 000018877).
Drug Selection
　 We choose the bosentan and sildenaﬁl as the 
PH-speciﬁc drug after the ASD occlusion.  Bosentan 
has been widely studied and used to treat PH patients 
associated with congenital heart diseases.  In the 
Bosentan Randomized Trial endothelin B receptor 
Antagonist Therapy-5 (BREATHE-5) showed that 
bosentan improved exercise capacity and hemodynam-
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Fig. 1　 Flow chart of the study. ASD, atrial septal defect; ECG, electrocardiogram; UCG, ultrasonic cardiography; 6MWD, 6-minute 
walk distance.
ics in patients with Eisenmenger syndrome ［7］.  Other 
study showed that long-term bosentan therapy leaded 
to symptomatic beneﬁt in exercise capacity and was 
well tolerated in PH patients with congenital heart 
diseases ［8］.  Sildenaﬁl has been studied to treat PH 
patients associated with congenital heart diseases ［9］.  
Sildenaﬁl is safe and well tolerated and improved 
exercise capacity and hemodynamics.  Sequential com-
bination therapy using bosentan and sildenaﬁl provided 
the favorable short-term hemodynamic results and good 
survival rates ［10］.  We choose the combination of 
bosentan and sildenaﬁl based on these studies.
Statistical Consideration
　 The eﬀects of our “Repair & Treat” strategy have 
not been determined in patients with PH and ASD.  
Thus,  we estimated the sample size based on the eﬀect 
of each treatment option on hemodynamics changes 
(ASD occlusion,  bosentan mono-therapy and sildenaﬁl 
mono-therapy in patients with PH).  Huang et al.  
investigated the short-term and medium-term results of 
transcatheter closure in patients with PH and ASD 
［11］.  In their study,  mean PAP decreased from 
42 mmHg to 35 mmHg and PVR decreased from 8.5 
wood units to 6.8 wood units after 12 months.  
Channick et al.  studied the eﬀects of bosentan on PAP 
and PVR in patients with PH.  In their study,  PVR 
decreased by 2.8 wood units and mean PAP decreased 
by 5 mmHg in patients who received bosentan ［12］.  
Galie et al.  studied the eﬀects of sildenaﬁl on PAP 
and PVR in patients with PH ［13］.  In their study,  
PVR decreased by 3.2 wood units and mean PAP 
decreased by 4.7 mmHg in patient who received with 
sildenaﬁl.  Based on the results of those studies,  we 
hypothesized that ASD closure followed by treatment 
with PH-speciﬁc drugs would decrease PVR by 8 
wood units compared with baseline.  We calculated 8 
subjects with an alpha level of 5 ,  a power of 80 .  
PAP and PVR obtained at baseline and at 12,  24,  48 
weeks were compared using 1-way repeated ANOVA,  
followed by the post-hoc Tukey test.  A p-value＜0.05 
was considered signiﬁcant.
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